Compare DexCom, Inc. (DXCM) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 2.4× DexCom, Inc.'s market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and MONDELEZ INTERNATIONAL INC Common Stock for 107 Days on average.
| DXCM | MDLZ | |
|---|---|---|
Market Cap | $31.86B | $77.43B |
Volume | 3,607,070 | 7,695,104 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $64.99 |
52-Week Low | $54.84 | $51.51 |
Typical Hold Time | 62 Days | 107 Days |
Enterprise Value | $31.32B | $97.78B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Mondelez International (MDLZ) trades at $60.67, up 2.17% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $0.73 exceeding expectations. Recent dividend increase to $0.52 per share and positive cash flow trends support the investment case. Valuation metrics include P/E of 22.22 and P/S of 1.97, while revenue growth continues with 2025 revenue reaching $38.54 billion.
MDLZ presents a compelling opportunity with 76% analyst buy ratings and $70.29 consensus price target representing 16% upside. The company demonstrates pricing power and emerging market momentum, though cocoa cost pressures and margin compression from 13.76% in 2023 to 6.36% in 2025 remain key watchpoints. Strong brand portfolio and defensive characteristics provide stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
